#1 Clinical Trials Search in Europe

Bemarituzumab

Bemarituzumab is an investigational drug being studied in clinical trials for the treatment of various types of cancer, particularly advanced gastric and gastroesophageal junction cancers. This article explores the ongoing research on bemarituzumab, its potential benefits, and its role in combination with other cancer therapies.

Table of Contents

What is Bemarituzumab?

Bemarituzumab (also known as AMG 552) is a new type of cancer drug called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that act like human antibodies in the immune system. They are designed to recognize and attach to specific proteins found on cancer cells[1].

How Does it Work?

Bemarituzumab specifically targets a protein called fibroblast growth factor receptor 2b (FGFR2b). This protein is found in higher than normal amounts (overexpressed) on the surface of some cancer cells. By attaching to FGFR2b, bemarituzumab may help to slow down or stop the growth of cancer cells[1][2].

What Cancers Does it Treat?

Bemarituzumab is being studied for the treatment of several types of cancer, including:

  • Gastric (stomach) cancer: This includes cancer of the stomach and the area where the stomach meets the esophagus (called the gastroesophageal junction)[3][4]
  • Squamous cell non-small cell lung cancer (SqNSCLC): A type of lung cancer that starts in the flat cells lining the airways[5]
  • Other solid tumors: Bemarituzumab is also being tested in various other types of solid tumors that have high levels of FGFR2b[1]

How is it Given?

Bemarituzumab is given as an intravenous (IV) infusion. This means it is delivered directly into your bloodstream through a vein. The frequency and duration of treatment can vary depending on the specific study and the type of cancer being treated[1][3].

Ongoing Research

Several clinical trials are currently underway to study bemarituzumab. These trials are looking at:

  • Effectiveness: Researchers are studying how well bemarituzumab works against different types of cancer, especially those with high levels of FGFR2b[1][3]
  • Combination treatments: Many studies are testing bemarituzumab in combination with other cancer treatments, such as chemotherapy or immunotherapy drugs[4][6]
  • Safety and side effects: Researchers are carefully monitoring patients to understand the potential side effects of bemarituzumab[1][5]
  • Personalized treatment: Some studies are using genetic tests to identify patients whose tumors have high levels of FGFR2b, as these patients may be more likely to benefit from bemarituzumab[7]

Potential Side Effects

As with any medical treatment, bemarituzumab may cause side effects. The full range of potential side effects is still being studied. Common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts. Researchers are carefully monitoring patients in clinical trials to identify any specific side effects related to bemarituzumab[3][5].

It’s important to note that bemarituzumab is still an experimental drug. This means it has not yet been approved by regulatory agencies like the FDA for widespread use. It is only available to patients participating in clinical trials. If you think you might be eligible for a trial involving bemarituzumab, talk to your oncologist about whether this could be an option for you[1][3].

Aspect Details
Drug Name Bemarituzumab (also known as AMG 552)
Primary Cancer Types Studied Advanced gastric cancer, gastroesophageal junction cancer
Other Cancer Types Solid tumors with FGFR2b overexpression, squamous-cell non-small-cell lung cancer
Administration Method Intravenous (IV) infusion
Treatment Approaches Monotherapy, combination with chemotherapy, combination with immunotherapy
Key Combination Therapies mFOLFOX6, CAPOX, nivolumab, docetaxel, pembrolizumab
Primary Outcome Measures Overall survival, progression-free survival, objective response rate
Secondary Outcome Measures Duration of response, disease control rate, safety and tolerability
Trial Phases Phase 1b, Phase 2, Phase 3

FAQ

  • What is bemarituzumab? Bemarituzumab is an investigational drug that targets a specific protein called FGFR2b, which is overexpressed in some types of cancer. It is being studied as a potential treatment for advanced gastric and gastroesophageal junction cancers, as well as other solid tumors.
  • How is bemarituzumab administered? Bemarituzumab is typically administered as an intravenous (IV) infusion. The dosage and frequency may vary depending on the specific clinical trial and treatment regimen.
  • What types of cancer is bemarituzumab being studied for? Bemarituzumab is primarily being studied for advanced gastric and gastroesophageal junction cancers. However, some trials are also investigating its use in other solid tumors with FGFR2b overexpression, including squamous-cell non-small-cell lung cancer.
  • Is bemarituzumab used alone or in combination with other treatments? Bemarituzumab is being studied both as a monotherapy and in combination with other cancer treatments. Many trials are investigating its use in combination with chemotherapy regimens and other targeted therapies or immunotherapies.
  • What are the main goals of the clinical trials involving bemarituzumab? The main goals of bemarituzumab clinical trials include evaluating its safety and tolerability, determining the most effective dosage, assessing its efficacy in treating various cancers, and studying its potential benefits when combined with other cancer treatments.

Ongoing Clinical Trials on Bemarituzumab

  • Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Germany Spain

  • Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Estonia France +12

  • Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +6

Glossary

  • FGFR2b: Fibroblast Growth Factor Receptor 2b, a protein that is overexpressed in some types of cancer and is the target of bemarituzumab.
  • Gastroesophageal Junction Cancer: Cancer that occurs at the area where the esophagus (the tube that carries food from the mouth to the stomach) meets the stomach.
  • Monotherapy: Treatment using a single drug or therapy approach.
  • mFOLFOX6: A chemotherapy regimen that combines oxaliplatin, leucovorin, and 5-fluorouracil (5-FU).
  • CAPOX: A chemotherapy regimen that combines capecitabine and oxaliplatin.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Dose-limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Treatment-emergent Adverse Event (TEAE): Any unfavorable and unintended sign, symptom, or disease that appears or worsens after starting a medical treatment.

References